# Copyright 2024-2025 SpectrixRD
# Licensed under the Apache License, Version 2.0
# See LICENSE file in the project root for full license text

"""
Regulatory Documentation Generator for CRISPR Therapies
========================================================

Generates IND-ready documentation including:
1. Safety Assessment Reports
2. CMC (Chemistry, Manufacturing, and Controls) documentation
3. Preclinical study templates
4. Clinical protocol outlines

Compliant with:
- FDA IND requirements (21 CFR 312)
- ICH guidelines (Q1-Q12, E6)
- Gene Therapy regulatory framework
"""

from datetime import datetime
from typing import Any, Dict, List


class RegulatoryDocGenerator:
    """
    Generate regulatory documentation for CRISPR gene therapies
    """

    def __init__(self):
        """Initialize regulatory doc generator"""
        self.fda_sections = self._load_fda_sections()

    def _load_fda_sections(self) -> Dict[str, List[str]]:
        """Load FDA IND application sections"""
        return {
            "Form_FDA_1571": [
                "Sponsor information",
                "Drug product name",
                "IND number (if amendment)",
                "Phase of clinical investigation",
                "Clinical investigators",
                "Previous IND information",
            ],
            "Introductory_Statement": [
                "Name of drug",
                "Active ingredients",
                "Pharmacological class",
                "Structural formula",
                "Dosage form and route",
                "Objectives and planned duration",
            ],
            "General_Investigational_Plan": [
                "Rationale for drug or study",
                "Indication(s) to be studied",
                "General approach",
                "Kinds of clinical trials planned",
                "Estimated number of patients",
            ],
            "Investigators_Brochure": [
                "Drug substance description",
                "Summary of pharmacological and toxicological effects",
                "Pharmacokinetics and biological disposition",
                "Summary of previous human experience",
                "Summary of adverse reactions",
            ],
            "Clinical_Protocol": [
                "Study objectives",
                "Investigator qualifications",
                "Patient selection criteria",
                "Study design",
                "Dosage and administration",
                "Clinical observations and tests",
                "Informed consent",
            ],
            "CMC_Information": [
                "Drug substance (gene construct)",
                "Drug product (final formulation)",
                "Placebo if applicable",
                "Labels and labeling",
                "Manufacturing information",
                "Stability data",
            ],
            "Pharmacology_Toxicology": [
                "Pharmacology studies",
                "Toxicology studies",
                "Genotoxicity studies",
                "Biodistribution studies",
                "Immunogenicity studies",
                "Integration site analysis",
            ],
            "Previous_Human_Experience": [
                "If any (published literature)",
                "Investigator-initiated studies",
                "Foreign clinical data",
            ],
        }

    def generate_safety_assessment(
        self,
        target_gene: str,
        grna_sequence: str,
        offtarget_results: Dict[str, Any],
        delivery_system: str,
    ) -> str:
        """
        Generate comprehensive safety assessment report

        Args:
            target_gene: Target gene
            grna_sequence: gRNA sequence
            offtarget_results: Off-target prediction results
            delivery_system: AAV or LNP

        Returns:
            Safety assessment report
        """
        report = f"""
================================================================================
CRISPR GENE THERAPY SAFETY ASSESSMENT REPORT
================================================================================

Date: {datetime.now().strftime("%Y-%m-%d")}
Protocol ID: CRISPR-{target_gene}-001
Gene Target: {target_gene}

================================================================================
1. EXECUTIVE SUMMARY
================================================================================

This safety assessment evaluates the potential risks associated with CRISPR/Cas9-
mediated gene editing targeting {target_gene} using guide RNA sequence:

gRNA: {grna_sequence}

Key Safety Findings:
âœ… Guide RNA specificity score: {offtarget_results.get('specificity_score', 'N/A')}/100
âœ… Predicted off-target sites: {offtarget_results.get('num_offtargets', 'N/A')}
âœ… Delivery system: {delivery_system}

================================================================================
2. GUIDE RNA SAFETY PROFILE
================================================================================

2.1 Sequence Analysis
---------------------
Guide RNA Sequence: {grna_sequence}
PAM Site: NGG (SpCas9)
GC Content: {offtarget_results.get('gc_content', 'N/A')}%
Seed Region GC: {offtarget_results.get('seed_gc', 'N/A')}%

2.2 Off-Target Risk Assessment
-------------------------------
Specificity Score: {offtarget_results.get('specificity_score', 'N/A')}/100
Risk Level: {offtarget_results.get('risk_level', 'To be determined')}

Potential Off-Target Sites: {offtarget_results.get('num_offtargets', 0)}
  - High risk (0-2 mismatches): {offtarget_results.get('high_risk_sites', 0)}
  - Medium risk (3 mismatches): {offtarget_results.get('medium_risk_sites', 0)}
  - Low risk (4+ mismatches): {offtarget_results.get('low_risk_sites', 0)}

2.3 Mitigation Strategies
--------------------------
âœ… Use high-fidelity Cas9 variants (e.g., SpCas9-HF1, eSpCas9)
âœ… Optimize delivery dose to minimize off-target editing
âœ… Perform GUIDE-seq or CIRCLE-seq validation
âœ… Monitor patients with whole-genome sequencing

================================================================================
3. DELIVERY SYSTEM SAFETY
================================================================================

Delivery Vector: {delivery_system}

{"AAV Safety Profile:" if "AAV" in delivery_system else "LNP Safety Profile:"}
- Immunogenicity: {"Medium (AAV capsid)" if "AAV" in delivery_system else "Low (lipid)"}
- Integration risk: {"Low (episomal)" if "AAV" in delivery_system else "None"}
- Pre-existing immunity: {"30-60% population" if "AAV" in delivery_system else "Minimal"}
- Dose-limiting toxicity: {"Hepatotoxicity" if "AAV" in delivery_system else "Transient inflammation"}

Safety Monitoring:
âœ… Anti-AAV antibody titers (baseline and follow-up)
âœ… Liver function tests (ALT, AST, bilirubin)
âœ… Complete blood count (CBC)
âœ… Inflammatory markers (CRP, IL-6)

================================================================================
4. GENOTOXICITY RISK ASSESSMENT
================================================================================

4.1 Chromosomal Translocations
-------------------------------
Risk Level: Low to Medium
Monitoring: Karyotyping and FISH analysis

4.2 Large Deletions
--------------------
Risk Level: Low (with optimized gRNA design)
Monitoring: Long-read sequencing (PacBio/Nanopore)

4.3 On-Target Mutations
------------------------
Risk Level: Minimal with validated gRNA
Monitoring: Sanger sequencing of edited locus

================================================================================
5. PRECLINICAL SAFETY STUDIES REQUIRED
================================================================================

5.1 In Vitro Studies (COMPLETED/PLANNED)
-----------------------------------------
â–¡ Cell viability assays
â–¡ Editing efficiency (% indels)
â–¡ Off-target analysis (GUIDE-seq/CIRCLE-seq)
â–¡ Chromosomal stability (karyotyping)

5.2 In Vivo Studies (REQUIRED FOR IND)
---------------------------------------
â–¡ Biodistribution study (GLP)
  - Dose: 1e12, 5e12, 1e13 vg/kg (AAV) or equivalent (LNP)
  - Timepoints: Days 1, 7, 28, 90
  - Tissues: Liver, spleen, heart, brain, gonads, injection site

â–¡ Toxicology study (GLP)
  - 13-week repeat dose toxicity
  - Species: Non-human primates (NHP) preferred
  - Endpoints: Clinical observations, hematology, chemistry, histopathology

â–¡ Integration site analysis
  - NGS-based integration mapping
  - Clonal expansion monitoring

â–¡ Reproductive/Developmental toxicity (if applicable)
  - Embryo-fetal development study
  - Pre/postnatal development study

================================================================================
6. CLINICAL MONITORING PLAN
================================================================================

6.1 Phase I Safety Endpoints
-----------------------------
Primary: Dose-limiting toxicities (DLTs)
Secondary: Adverse events (AEs), serious AEs (SAEs)

6.2 Monitoring Schedule
------------------------
Baseline: Complete medical history, labs, imaging
Weekly (Months 1-3): Safety labs, AE monitoring
Monthly (Months 4-12): Safety labs, efficacy markers
Quarterly (Years 2-5): Long-term safety monitoring
Annually (Years 6-15): Long-term follow-up (FDA requirement)

6.3 Safety Stopping Rules
--------------------------
âœ… Grade 4 treatment-related AE (except transient lab abnormalities)
âœ… Grade 3 treatment-related AE in > 33% of patients
âœ… Any case of clonal expansion or malignancy
âœ… Severe immunogenicity requiring immunosuppression

================================================================================
7. RISK-BENEFIT ASSESSMENT
================================================================================

Potential Benefits:
âœ… Permanent genetic correction
âœ… Disease modification or cure
âœ… Reduced need for lifelong medication

Potential Risks:
âš ï¸  Off-target editing (mitigated by high-fidelity Cas9)
âš ï¸  Immunogenicity (manageable with immunosuppression)
âš ï¸  Unknown long-term effects (15-year follow-up required)

Overall Assessment: {"FAVORABLE for clinical development" if offtarget_results.get('specificity_score', 0) > 70 else "REQUIRES OPTIMIZATION before clinical development"}

================================================================================
8. REGULATORY RECOMMENDATIONS
================================================================================

âœ… RECOMMENDED NEXT STEPS:
1. Complete in vitro off-target validation (GUIDE-seq/CIRCLE-seq)
2. Conduct GLP biodistribution and toxicology studies
3. Develop CMC documentation for vector manufacturing
4. Prepare clinical protocol and informed consent
5. Submit pre-IND meeting request to FDA

ðŸ“‹ IND Application Target: 18-24 months from now

================================================================================
9. REFERENCES
================================================================================

1. FDA Guidance: Human Gene Therapy for Rare Diseases (2020)
2. FDA Guidance: Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy INDs (2020)
3. ICH E6(R2): Good Clinical Practice
4. Doench et al. (2016) Nat Biotechnol - Optimized sgRNA design
5. Hsu et al. (2013) Nat Biotechnol - DNA targeting specificity

================================================================================
REPORT PREPARED BY: BioQL Quantum CRISPR Design System v5.4.4
CONFIDENTIAL - FOR REGULATORY SUBMISSION PURPOSES ONLY
================================================================================
"""

        return report

    def generate_ind_checklist(self, target_gene: str, disease: str) -> str:
        """
        Generate IND application checklist

        Args:
            target_gene: Target gene
            disease: Disease indication

        Returns:
            IND checklist
        """
        checklist = f"""
================================================================================
IND APPLICATION CHECKLIST
================================================================================

Gene Therapy Product: CRISPR/Cas9 targeting {target_gene}
Indication: {disease}
Date: {datetime.now().strftime("%Y-%m-%d")}

================================================================================
SECTION 1: ADMINISTRATIVE (Form FDA 1571)
================================================================================

â–¡ Form FDA 1571 (signed by sponsor or authorized representative)
â–¡ Table of contents
â–¡ Introductory statement and general investigational plan
â–¡ Name and qualifications of investigators
â–¡ Statement of investigator (Form FDA 1572) for each PI

================================================================================
SECTION 2: DRUG PRODUCT INFORMATION
================================================================================

â–¡ Investigator's Brochure
  â–¡ Physical, chemical, and pharmaceutical properties
  â–¡ Formulation
  â–¡ Pharmacological and toxicological effects (animals)
  â–¡ Pharmacokinetics and biological disposition
  â–¡ Previous human experience

================================================================================
SECTION 3: CLINICAL PROTOCOL
================================================================================

â–¡ Study title and protocol number
â–¡ Objectives and rationale
â–¡ Investigator qualifications and experience
â–¡ Patient selection criteria
  â–¡ Inclusion criteria
  â–¡ Exclusion criteria
â–¡ Study design and methodology
  â–¡ Phase (I, II, or III)
  â–¡ Control group (if any)
  â–¡ Randomization and blinding
â–¡ Dose escalation plan (for Phase I)
â–¡ Clinical endpoints
  â–¡ Primary endpoints
  â–¡ Secondary endpoints
  â–¡ Exploratory endpoints
â–¡ Safety monitoring plan
  â–¡ Adverse event reporting
  â–¡ Data Safety Monitoring Board (DSMB) charter
â–¡ Statistical considerations
â–¡ Informed consent document

================================================================================
SECTION 4: CMC (CHEMISTRY, MANUFACTURING, AND CONTROLS)
================================================================================

â–¡ Drug Substance (Gene Construct)
  â–¡ Vector map and sequence
  â–¡ Plasmid construction
  â–¡ Sequence verification
  â–¡ Stability data

â–¡ Drug Product (Final Formulation)
  â–¡ Description and composition
  â–¡ Manufacturing process
    â–¡ Cell line (for AAV: HEK293, SF9, etc.)
    â–¡ Transfection/infection method
    â–¡ Purification method
    â–¡ Formulation and fill/finish
  â–¡ Process controls and validation
  â–¡ Batch records (3 representative batches)
  â–¡ Characterization
    â–¡ Identity (PCR, sequencing)
    â–¡ Purity (SDS-PAGE, Western blot, ddPCR)
    â–¡ Potency (in vitro transduction assay)
    â–¡ Safety (sterility, endotoxin, mycoplasma, RCR/RCL)

â–¡ Container Closure System
â–¡ Stability data (at least 3 time points)
â–¡ Label and labeling
  â–¡ Immediate container label
  â–¡ Outer package label
  â–¡ Investigational use statement

================================================================================
SECTION 5: PHARMACOLOGY AND TOXICOLOGY
================================================================================

â–¡ Pharmacology Studies
  â–¡ Mechanism of action
  â–¡ In vitro editing efficiency
  â–¡ Off-target analysis (computational + experimental)

â–¡ Toxicology Studies (GLP-compliant)
  â–¡ Biodistribution study
    â–¡ Species: Non-human primate (preferred)
    â–¡ Dose levels: 3 (including clinical dose)
    â–¡ Timepoints: 1, 7, 28, 90 days
    â–¡ Tissues analyzed: 20+ organs
    â–¡ Endpoints: Vector DNA, mRNA, protein
  â–¡ Repeat-dose toxicity study (13-week or 26-week)
    â–¡ Species: NHP
    â–¡ Dose levels: 3 + vehicle control
    â–¡ Clinical observations daily
    â–¡ Hematology and clinical chemistry
    â–¡ Histopathology (all major organs)
  â–¡ Genotoxicity studies
    â–¡ Integration site analysis
    â–¡ Chromosomal aberration test
  â–¡ Reproductive toxicology (if indicated)
  â–¡ Immunogenicity and immunotoxicity

â–¡ Study Reports
  â–¡ GLP statement
  â–¡ Quality assurance inspections
  â–¡ Data tables and individual animal data
  â–¡ Pathology peer review

================================================================================
SECTION 6: PREVIOUS HUMAN EXPERIENCE
================================================================================

â–¡ Literature search results
â–¡ Published clinical data (if any)
â–¡ Foreign regulatory approvals
â–¡ Investigator-initiated trials

================================================================================
SECTION 7: ADDITIONAL INFORMATION
================================================================================

â–¡ Gene Therapy Appendix
  â–¡ Vector design and construct
  â–¡ Vector production and testing
  â–¡ Biodistribution and persistence
  â–¡ Integration studies (for integrating vectors)
  â–¡ Shedding studies
  â–¡ Patient follow-up plan (15 years per FDA)

â–¡ Institutional Review Board (IRB) information
  â–¡ List of participating institutions
  â–¡ IRB approval letters (can be submitted later)

â–¡ Other
  â–¡ Environmental assessment (or categorical exclusion)
  â–¡ Previous IND correspondence (if applicable)
  â–¡ Any additional data requested by FDA

================================================================================
SUBMISSION TIMELINE
================================================================================

Recommended Timeline for IND Submission:

Months -24 to -18: Construct optimization, pilot manufacturing
Months -18 to -12: GLP biodistribution study
Months -12 to -6:  GLP toxicology study (13-week)
Months -6 to -3:   CMC process validation, analytical method development
Months -3 to -1:   IND document compilation, quality review
Month 0:           IND submission to FDA
Day 30:            FDA response (clinical hold or proceed)
Month 1-2:         IRB submissions and site initiation
Month 2-3:         First patient enrollment (if no clinical hold)

================================================================================
ESTIMATED COSTS (USD)
================================================================================

GLP Studies:                     $2-5 million
Vector Manufacturing (GMP):      $1-3 million
Analytical Development:          $500K - $1M
Regulatory Consulting:           $200K - $500K
Clinical Site Setup:             $500K - $1M

TOTAL PRE-IND COSTS:            $4.2 - $10.5 million

================================================================================
CONTACT INFORMATION
================================================================================

FDA Division: Division of Cellular and Gene Therapies (DCGT)
Office: Office of Tissues and Advanced Therapies (OTAT)
Center: CBER (Center for Biologics Evaluation and Research)

Pre-IND Meeting: HIGHLY RECOMMENDED
Submit request: 3 months before intended IND submission
Meeting occurs: ~60 days after request
Topics: CMC strategy, nonclinical program, clinical trial design

================================================================================
CHECKLIST GENERATED BY: BioQL Quantum CRISPR Design System v5.4.4
CONFIDENTIAL - FOR INTERNAL USE ONLY
================================================================================
"""

        return checklist


if __name__ == "__main__":
    # Test regulatory doc generation
    generator = RegulatoryDocGenerator()

    print("=" * 80)
    print("Regulatory Documentation Generator - Test")
    print("=" * 80)
    print()

    # Generate safety assessment
    offtarget_results = {
        "specificity_score": 85.3,
        "gc_content": 55.0,
        "seed_gc": 62.5,
        "risk_level": "LOW",
        "num_offtargets": 3,
        "high_risk_sites": 0,
        "medium_risk_sites": 1,
        "low_risk_sites": 2,
    }

    report = generator.generate_safety_assessment(
        "PCSK9", "GATACCATGATCACGAAGGT", offtarget_results, "AAV8"
    )

    print(report[:2000])  # Print first 2000 chars
    print("...")
    print(f"\nâœ… Full safety report generated ({len(report)} characters)")
    print()

    # Generate IND checklist
    checklist = generator.generate_ind_checklist("PCSK9", "Hypercholesterolemia")
    print("âœ… IND checklist generated")
    print(f"   Sections: {len(generator.fda_sections)}")
    print(f"   Length: {len(checklist)} characters")
